利妥昔单抗对费城染色体阴性急性淋巴细胞白血病CD20微小残留病清除的疗效
Rituximab efficacy for minimal residual disease eradication in philadelphia-negative acute lymphoblastic leukemia CD20.
作者信息
Cecchi Nicola, Sciumè Mariarita, Ricchiuti Antony, Bosi Alessandro, Tagliaferri Elena, Passamonti Francesco, Fracchiolla Nicola Stefano
机构信息
University of Milan, Milan, Italy.
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
出版信息
Ann Hematol. 2025 May 16. doi: 10.1007/s00277-025-06332-y.
Rituximab has never been investigated in MRD persistence/relapse. We describe a clinical picture of a woman with Ph-negative B-ALL CD20, ineligible to allogeneic transplant, achieving MRD eradication using rituximab monotherapy after frontline chemotherapy and blinatumomab failure. This demonstrates rituximab's potential in MRD Ph-negative B-ALL CD20, warranting further clinical investigation.
利妥昔单抗从未在微小残留病（MRD）持续存在/复发方面进行过研究。我们描述了一名Ph阴性B淋巴细胞白血病（B-ALL）且表达CD20的女性患者的临床情况，该患者不符合异基因移植条件，在一线化疗和博纳吐单抗治疗失败后，使用利妥昔单抗单药治疗实现了MRD清除。这证明了利妥昔单抗在Ph阴性B-ALL CD20的MRD治疗中的潜力，值得进一步的临床研究。
Zotero 插件